Clinical utility of CKMB isoform determinations in patients who present to the emergency department with continuous or resolved chest pain

Predictive Value of Prothrombin Time for All-cause Mortality in Acute Myocardial Infarction Patients

Acute myocardial infarction (AMI) is a serious cardiovascular disease caused by acute or persistent ischemic and anoxia of the coronary artery. A more practical and effective risk model is still remained to be established for AMI patients. This study aims to investigate the predictive value of prothrombin time (PT) in AMI patients. In this study, 2734 AMI patients available in the public MIMIC III clinical database were investigated, with 629 deaths occurring within 2-year follow-up. More than 20 risk factors including demographics, clinical disease history, laboratory test information, surgery history, and mediation information were analyzed as potential predictors for all-cause mortality in AMI patients. After adjustment for other covariates, PT was showed to be a significant risk factor for all-cause mortality in AMI patients (adjusted hazard ratio, 4.04; 95% confidence interval, 2.83 to 5.75) from Cox regression analysis. We also developed a comprehensive risk model for AMI mortality using multivariate Cox proportional hazards model based on the above 20 risk factors. Combined with PT, the model achieved a good accuracy with an AUC (area under ROC curve) of 0.843. Overall, PT is an independent predictor for 2-year mortality in AMI, and it might be useful in identifying AMI patients with a high risk for mortality.

Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein

Human parvovirus B19 (B19) infection has been postulated to both myocardial injury and development of systemic lupus erythematosus (SLE). However, the influence of anti-B19-VP1u antibodies on cardiac disorders in SLE is still obscure. To elucidate the effects of anti-B19-VP1u IgG in SLE, passive transfer of PBS, normal rabbit IgG or rabbit anti-B19-VP1u IgG was injected intravenously into NZB/W F1 mice, respectively. Significant expression of IL-1β, IL-6 and TNF-α were detected in NZB/W F1 mice receiving rabbit anti-B19-VP1u IgG. Markedly cardiomyocyte disarray and lymphocyte infiltration were observed in left ventricle of hearts from NZB/W F1 mice receiving rabbit anti-B19-VP1u IgG. Additionally, significant increases of matrix metalloproteinase-9 (MMP9) activity and protein expression were detected in left ventricle of hearts from NZB/W F1 mice receiving B19-VP1u IgG. Accordingly, significant increase of phosphorylated p-38 and NF-κB proteins were observed in left ventricle of hearts from NZB/W F1 mice receiving B19-VP1u IgG. However, no significant variation of cardiac atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), heart-type fatty acid-binding protein (h-FABP) and creatine kinase MB (CK-MB) were detected among all experimental groups. These findings firstly demonstrated the aggravated effects of anti-B19 VP1u IgG on cardiac injury by induction of inflammatory but not myocardial infarction-associated proteins through activation of phosphorylated p-38 and NF-κB signaling.